Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Harris Associates Concentrated Strategy. This analysis is provided for institutional research purposes only and is not investment advice.
"The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in detracted holdings like Keurig Dr Pepper and Molina Healthcare."
In the third quarter of 2025, the U.S. Concentrated Strategy returned 2.39% net of fees, underperforming the Russell 1000 Value Index's return of 5.33%. Key quarterly contributors included Warner Bros Discovery (on Paramount-Skydance merger interest), Alphabet (driven by legal clarity and cloud-based AI growth), and IQVIA Holdings. Detractors included Keurig Dr Pepper, Molina Healthcare, and Salesforce, though the manager retains strong long-term conviction in all three, viewing their setbacks as temporary. The portfolio had zero turnover this period, with no new positions initiated and no final sales completed.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Growth Outlook
Market outlook remains above average conviction: The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Risk Appetite
Risk appetite posture is above average conviction: The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Capital Deployment
Capital deployment remained balanced with selective rotation across positions. The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Forward Guidance
Forward guidance signal: The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Language Signal
Tone analysis indicates above average conviction language: The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
Time Horizon
Investment time horizon reflects a high conviction orientation. The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in de...
